Koot, Like your article. I pretty much agree on the FDA having to approve this round for chronic DME. I'm a little surprised ALIM didn't go for this approach from the beginning. Retina
specialists will use it off label anyway. They just need some tools to work with. Why do you think they never assembled an advisory panel? They would have received resounding support for approval. Looking forward to resubmission.